InflaRx N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IFRX research report →
Range $9 – $9
Price Chart
About the company
InflaRx N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States.
- CEO
- Niels C. Riedemann
- IPO
- 2017
- Employees
- 65
- HQ
- Jena, TH, DE
Get TickerSpark's AI analysis on IFRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $232.72M
- P/E
- -2.89
- PEG
- -0.08
- P/S
- -20599.68
- P/B
- 1.14
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- 48201.61%
- Op Margin
- 362271.47%
- Net Margin
- 387532.08%
- ROE
- -58.00%
- ROIC
- -24.89%
Latest fiscal year · YoY change
- Revenue
- $29.33K-82.3%
- Gross Profit
- $-7,238,287-129.7%
- Op Income
- $-48,256,974
- Net Income
- $-45,633,780+0.9%
- EPS
- $-0.66+15.4%
- OCF Growth
- +30.1%
- FCF Growth
- +30.0%
- 52W High
- $2.95
- 52W Low
- $0.80
- 50D MA
- $1.99
- 200D MA
- $1.59
- Beta
- 2.61
- RSI (14)
- 27
- Avg Volume
- 809.70K
No earnings-call transcripts are available for IFRX yet.
- Free Float
- 87.2%
- Shares Outstanding
- 147.29M
- Float Shares
- 128.45M
of shares held by institutions
37 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Suvretta Capital Management, LLC | 22.93M | ▲ 15.00M |
| Tcg Crossover Management, LLC | 14.50M | ▲ 14.50M |
| Fmr LLC | 8.16M | ▲ 8.16M |
| Commodore Capital LP | 7.30M | ▲ 7.30M |
| Spruce Street Capital LP | 5.35M | ▲ 5.35M |
| 683 Capital Management, LLC | 5.07M | ▲ 1.75M |
| Farallon Capital Management LLC | 3.33M | ▲ 3.33M |
| Stempoint Capital LP | 3.23M | ▲ 3.23M |
| Great Point Partners LLC | 3.05M | ▲ 3.05M |
| Adar1 Capital Management, LLC | 3.00M | ▲ 2.84M |
| Kalehua Capital Management LLC | 2.90M | ▲ 2.90M |
| Ameriprise Financial Inc | 2.57M | ▲ 2.57M |
Held by 15 ETFs
Biggest fund positions in IFRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Brudnick Richard | other | 0 |
| Mar 18, 26 | Brudnick Richard | other | 30,000 |
| Mar 18, 26 | Brudnick Richard | other | 30,000 |
| Mar 18, 26 | Brudnick Richard | other | 30,000 |
| Mar 18, 26 | Brudnick Richard | other | 30,000 |
| Mar 18, 26 | Brudnick Richard | other | 30,000 |
| Mar 18, 26 | Hellstrom Hege | other | 22,500 |
| Mar 18, 26 | Hellstrom Hege | other | 30,000 |
| Mar 18, 26 | Hellstrom Hege | other | 30,000 |
| Mar 18, 26 | Hellstrom Hege | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IFRX coverage
Recent articles, reports, and earnings notes.
No research on IFRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IFRX report →InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
globenewswire.com · Oct 2
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
globenewswire.com · Oct 1
InflaRx to Host Virtual Capital Markets Day
globenewswire.com · Sep 21
InflaRx Announces Participation in September Investor Conferences
globenewswire.com · Aug 20
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
globenewswire.com · Aug 6
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
globenewswire.com · Jul 30
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
defenseworld.net · Jul 26
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.